RARE ▼ -4.3% - Ultragenyx Pharmaceutical Inc. $RARE Wells Fargo analyst Benjamin Burnett raised the firm's price target on Ultragenyx to $19 from $18 and keeps an Equal Weight rating on the shares. The firm likes the mindset that Ultragenyx is embracing on profitability, as it believes right-sizing expenses while also funding clinical catalysts is more sustainable. Wells remains on the sidelines throughout the transition, and looks to OTC data in the first half of 2027 as a key event. 04-NOV-2026 07:39 AM ET